Extended Data Fig. 12: Model predicted outcomes of TrkA cell inhibitor treatments are corroborated by cell images.

(A) Model predicted DPD responses of TrkA cells to ERBB and MEK inhibitors are shown at 45 min 100 ng/ml NGF stimulation by Loewe isoboles. The ERBB inhibitor applied alone has a negligible effect. (B) The percentages of differentiated TrkA cells show that a combination of ERBB (Gefitinib, GEF) and MEK inhibitors (Trametinib, TRAM) does not change the cell state, as correctly predicted by the model. Data are presented as mean values +/- SEM for n = 3 biologically independent experiments. (C) Live cell images of NGF-stimulated TrkA cells treated with 2.5 μM Gefitinib, 0.2 μM Trametinib and a combination of 1.25 μM Gefitinib and 0.1 μM Trametinib taken at 72 h. Representative images of 3 biological replicates are shown.